Marksans Pharma Limited reported its highest-ever profitability for FY26, with consolidated revenue crossing the ₹3,000 crore mark to reach ₹3,033 crore and profit after tax (PAT) rising to ₹420 crore. The pharmaceutical company’s performance was driven by a 24% year-on-year surge in North American sales and significant margin expansion, culminating in an EBITDA of ₹601 crore with a margin of 20.4%. This financial strength has enabled the Board of Directors to recommend a final dividend of ₹0.90 per equity share, subject to shareholder approval at the 34th Annual General Meeting (AGM) on August 27, 2026.

The Board meeting held on May 26, 2026, also approved the re-appointment of Mrs. Sandra Saldanha as Whole-time Director for three years, effective September 25, 2026. Her proposed annual remuneration is ₹72,17,928. Additionally, Dr. Sunny Sharma retires by rotation and offers himself for re-appointment. The AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM), with remote e-voting open from August 24 to August 26, 2026.

Financial Performance Highlights

Marksans Pharma’s FY26 results reflect robust operational execution and disciplined cost management. Operating revenue grew by 12.5% to ₹2,951 crore, while gross profit increased by 13.2% to ₹1,674 crore, pushing the gross margin to 56.7%. The company generated operating cash flows of ₹458 crore and free cash flows of ₹328 crore, ending the year with cash reserves of approximately ₹990 crore and maintaining a debt-free balance sheet.

| Metric | FY26 Value | YoY Change | | ---: | :--- | | Consolidated Revenue | ₹3,033 crore | ~12.5% | | Profit After Tax (PAT) | ₹420 crore | Highest ever | | EBITDA | ₹601 crore | Margin: 20.4% | | Operating Cash Flow | ₹458 crore | N/A | | Cash & Equivalents | ₹990 crore | N/A |

Geographic Growth Drivers

North America remained the largest and fastest-growing market, contributing approximately 52% of total revenue. Sales in this region grew by 24% to ₹1,533 crore, supported by the launch of 112 new SKUs and strong market share gains. The United Kingdom business also showed resilience, delivering record quarterly revenue in Q4FY26 after a challenging start to the year. Meanwhile, the Australia and New Zealand segment grew by 20% to ₹303 crore, bolstered by the strategic entry into the prescription segment through Nova Pharma.

What the Numbers Show

The divergence between revenue growth (12.5%) and gross profit growth (13.2%) indicates improved operating leverage and favorable product mix shifts. With EBITDA margins expanding to 20.4% from lower levels in previous periods, Marksans Pharma is successfully transitioning from volume-driven growth to value-driven profitability. The debt-free status combined with ₹990 crore in cash provides substantial flexibility for future R&D investments, which stood at ₹89 crore in FY26, or approximately 3% of consolidated revenue. This capital position supports the company’s strategic roadmap of filing over 200 products in the UK market over the next four years.

Dividend and Shareholder Details

The recommended final dividend of ₹0.90 per share represents a total cash outflow of ₹407.85 million. The record date for dividend entitlement is August 20, 2026, with payment scheduled on or after September 8, 2026. Shareholders must ensure their KYC and bank details are updated to receive electronic dividends. Unclaimed dividends from FY2018-19 will be transferred to the Investor Education and Protection Fund (IEPF) by November 1, 2026, urging shareholders to claim pending amounts promptly.

Marksans Pharma has scheduled its earnings conference call for the first quarter of fiscal year 2027 on Thursday, August 13, 2026, at 4:30 PM IST. The management team will present and discuss the company's unaudited financial results for the quarter ended June 30, 2026, covering both standalone and consolidated performance metrics. This disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with notifications submitted to BSE Limited and the National Stock Exchange of India Limited on August 03, 2026.

Conference Call Leadership

Founder, Chairman and Managing Director Mark Saldanha and Chief Financial Officer Jitendra Sharma are scheduled to lead the discussion. DAM Capital Advisors Ltd will manage the proceedings, with Nitin Agarwal serving as the analyst lead. For further assistance regarding the call logistics, DAM Capital Advisors Limited can be contacted at +91 22 4202 2568 / 2638 or via email at nitin.a@damcapital.in and payal@damcapital.in .

Dial-in Access Details

Participants can access the call via universal dial-in numbers +91 22 6280 1384 or +91 22 7115 8285. Investors are advised to dial in five to ten minutes prior to the scheduled start time to ensure connectivity. A diamond passcode link is also available for access. International participants may use the toll-free numbers provided for specific regions, as detailed below:

Post-Call Resources

Following the conference call, Marksans Pharma will host the presentation, audio recording, and transcript on its official website. These materials will be available at https://www.marksanspharma.com/earnings-call-transcripts.html for public access. The notice was signed by Harshavardhan Panigrahi, Company Secretary.